申请人:Warner-Lambert Company LLC
公开号:US06642256B2
公开(公告)日:2003-11-04
Described are piperidines of Formula I
and pharmaceutically acceptable salts thereof. The compounds of Formula I are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.
本文描述的是公式I的哌啶类化合物及其药物可接受的盐。公式I的化合物是NMDA受体通道复合物的拮抗剂,可用于治疗脑血管疾病,例如中风、脑缺血、中枢神经系统疾病、抑郁症、创伤、低血糖、神经退行性疾病、焦虑、偏头痛、惊厥、帕金森病、氨基糖苷类抗生素引起的听力损失、精神病、青光眼、CMV视网膜炎、阿片类药物耐受或戒断、疼痛,尤其是慢性疼痛、神经病理性疼痛或手术疼痛,以及尿失禁。